CliffBio
small molecule

IDVYNSO

DORAVIRINE; ISLATRAVIR

Loss of exclusivityAugust 2032latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME LLC

Drug detail

Brand nameIDVYNSO
Active ingredientDORAVIRINE; ISLATRAVIR
Strength100MG;0.25MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2026
Marketing statusRX

Listed patents

PatentExpiresType
8486975August 2032substance, product
7339053May 2027substance

Regulatory exclusivity

CodeExpires
NCEApril 2031

More from MERCK SHARP AND DOHME LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.